Novo Nordisk Stock Jumps on Early Stage Weight-Loss Drug Trial Results
Novo Nordisk's (NVO) U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.
BA's $3.5B Loss, NVO Weight Loss Drug Trial, AXP Down on Strong Earnings
"It's difficult to find what we're not liking" for American Express's (AXP) earnings, says Jenny Horne. A strong report bolstered by a big holiday shopping season wasn't enough to impress investors.
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
NVO Weight-Loss Drug Gets Positive Data
Novo Nordisk (NVO) pops on positive drug trial results. The company showed a 22% reduction in weight for obese and overweight patients after 36 weeks.
Ozempic maker's stock surges. A trial of a new Novo Nordisk drug shows promise.
Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much as 22%.
Novo Nordisk's Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock Soars
On Friday, Novo Nordisk A/S NVO released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration.
Novo Nordisk Stock Soars on New Weight-Loss Drug Results
The Danish drugmaker announced new data for its new weight-loss drug Amycretin Friday.
Novo Nordisk shares pop 10% on early-stage weight loss drug trial results
The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.
Novo Nordisk reports 22% weight loss in early subcutaneous amycretin trial
Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous administration, saying people with obesity or overweight treated with the drug achieved a 22% weight loss after 36 weeks.
Is Novo Nordisk (NVO) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Novo Nordisk (NVO) Stock Dips While Market Gains: Key Facts
In the latest trading session, Novo Nordisk (NVO) closed at $80.57, marking a -0.57% move from the previous day.
NVO Stock Down as Medicare Selects Semaglutide Drugs for Price Cuts
Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price negotiations in 2025.
